NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68788-8666-03 | 68788-8666 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 14, 2024 | In Use | |
70710-1745-03 | 70710-1745 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
80425-0228-02 | 80425-0228 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 28, 2023 | In Use | |
63629-6621-09 | 63629-6621 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 28, 2015 | Sep 30, 2018 | In Use |
16714-0929-01 | 16714-0929 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Mar 20, 2020 | In Use | |
50090-6259-00 | 50090-6259 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 7, 2022 | In Use | |
59651-0530-03 | 59651-0530 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
54868-5801-03 | 54868-5801 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 30, 2007 | In Use | |
55111-0686-07 | 55111-0686 | Gemcitabine | gemcitabine | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 25, 2011 | In Use | |
67877-0288-33 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 30, 2020 | In Use | |
72606-0555-01 | 72606-0555 | Capecitabine | Capecitabine 500mg | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 6, 2019 | In Use | |
68788-8377-06 | 68788-8377 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 28, 2023 | In Use | |
68001-0543-41 | 68001-0543 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 1, 2022 | In Use | |
00085-3004-02 | 00085-3004 | Temozolomide | Temodar | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | Oct 22, 2014 | In Use |
00245-0570-01 | 00245-0570 | Isotretinoin | Isotretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 21, 2021 | In Use | |
00245-0822-30 | 00245-0822 | Everolimus | TORPENZ | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
59651-0634-03 | 59651-0634 | ISOTRETINOIN | ISOTRETINOIN | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan 29, 2024 | In Use | |
16714-0150-01 | 16714-0150 | Triamcinolone Acetonide | Triamcinolone Acetonide | 400.0 mg/10mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Nov 19, 2019 | In Use | |
50090-1990-01 | 50090-1990 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 17, 2015 | In Use | |
67296-1886-05 | 67296-1886 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 24, 2022 | In Use | |
71329-0105-01 | 71329-0105 | Prednisone | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 4, 2018 | In Use | |
72578-0166-01 | 72578-0166 | Dexamethasone | Dexamethasone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 13, 2024 | In Use | |
71335-2500-02 | 71335-2500 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 23, 2024 | In Use | |
00703-5233-93 | 00703-5233 | Daunorubicin Hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Apr 1, 2004 | Jun 30, 2016 | In Use |
00378-0274-25 | 00378-0274 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Feb 20, 2003 | Jul 12, 2016 | In Use |
Found 11765 results — Export these results